Even as India’s largest drug maker, Ranbaxy, is confident of launching its first “new drug” by January 2012 to combat malaria in the country, the global euphoria the potential drug had generated in

The country’s drug regulator has given conditional market approval for Ranbaxy Laboratories’ anti-malaria drug, paving the way for the launch of the country’s first privately-developed medicine and

Drug major Ranbaxy On Wednesday said it will spend nearly ¥200 million (over Rs 10 crore) along with parent company Daiichi Sankyo over the next five years to sponsor mobile healthcare field clinic

Daiichi Sankyo Company and Ranbaxy Laboratories Ltd on Wednesday announced an initiative to sponsor mobile healthcare field clinics in India, Cameroon and Tanzania as part of their global social co

Pfizer Inc and Dr Reddy’s Laboratories have settled a patent infringement suit related to the Indian drug maker’s launch of a generic version of the blockbuster drug, Lipitor, in the US.

No major deficiency found during inspection of Ranbaxy, Orchid, Emcure, Nectar & Ind Swift Facilities

The US drug regulator has inspected manufacturing plants of at least half a dozen Indian drugmakers in the last few weeks, raising hopes among some of these companies that they will shortly be able to export medicines to the world's largest drug market.
Several industry executives said teams o

Co may resume supplies to the US nearly 3 years after they were halted from its 2 plants

American drug authorities have started inspecting Ranbaxy Laboratories

Global drugmakers have started launching generic or low-priced version of popular medicines and have slashed prices of their existing products to increase market share in India, taking on local competitors in their own game.

French drugmaker Sanofi Aventis has launched a range of generic drugs, some at half the price of competing brands of local companies, while Japan

Dr S. Chandrashekar, a Director-grade scientist at the Indian Institute of Chemical Technology (IICT) here was selected for the Ranbaxy Research Award for the year 2009. Dr Chandrashekar was chosen for his exemplary work in the area of pharmaceutical sciences, according to a release.

THE Delhi High Court (HC) has turned down Bristol-Myers Squibb